GEP20257757B - Therapeutic derivatives of interleukin-22 - Google Patents

Therapeutic derivatives of interleukin-22

Info

Publication number
GEP20257757B
GEP20257757B GEAP202015970A GEAP2020015970A GEP20257757B GE P20257757 B GEP20257757 B GE P20257757B GE AP202015970 A GEAP202015970 A GE AP202015970A GE AP2020015970 A GEAP2020015970 A GE AP2020015970A GE P20257757 B GEP20257757 B GE P20257757B
Authority
GE
Georgia
Prior art keywords
linker
variant
seq
fatty acid
hil
Prior art date
Application number
GEAP202015970A
Other languages
English (en)
Inventor
Rasmus Jørgensen
Kristian Sass-Ørum
Michael Paolo Bastner Sandrini
Thomas Hoeg-Jensen
Henning Thøgersen
Sebastian Beck Jørgensen
Original Assignee
Cytoki Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoki Pharma Aps filed Critical Cytoki Pharma Aps
Publication of GEP20257757B publication Critical patent/GEP20257757B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
GEAP202015970A 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22 GEP20257757B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22

Publications (1)

Publication Number Publication Date
GEP20257757B true GEP20257757B (en) 2025-04-10

Family

ID=68502950

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202015970A GEP20257757B (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22
GEAP202415970A GEAP202415970A (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202415970A GEAP202415970A (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Country Status (19)

Country Link
US (5) US11806403B2 (OSRAM)
EP (2) EP3819307A1 (OSRAM)
JP (2) JP2023502005A (OSRAM)
KR (1) KR20220097921A (OSRAM)
CN (2) CN114761422B (OSRAM)
AU (1) AU2020378648A1 (OSRAM)
BR (1) BR112022008497A2 (OSRAM)
CA (1) CA3160338A1 (OSRAM)
CL (1) CL2022001185A1 (OSRAM)
CO (1) CO2022005889A2 (OSRAM)
CR (1) CR20220249A (OSRAM)
GE (2) GEP20257757B (OSRAM)
IL (1) IL292657A (OSRAM)
MX (1) MX2022005547A (OSRAM)
MY (1) MY209488A (OSRAM)
PE (1) PE20221279A1 (OSRAM)
PH (1) PH12022551107A1 (OSRAM)
SA (1) SA522432487B1 (OSRAM)
WO (1) WO2021089875A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
MX2022012822A (es) * 2020-04-17 2023-01-04 Univ Leland Stanford Junior Polipeptidos modificados de interleucina-22 y usos de los mismos.
EP4389138A1 (en) 2022-12-22 2024-06-26 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
EP4637803A2 (en) 2022-12-22 2025-10-29 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
CN119708194A (zh) * 2023-09-28 2025-03-28 南京诺艾新生物技术有限公司 Il-22突变体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (OSRAM) 1964-12-21
WO2009117640A2 (en) 2008-03-21 2009-09-24 Wyeth Antibodies against interleukin-10 like cytokines and uses therefor
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
TW201143790A (en) * 2010-05-13 2011-12-16 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
PL2654794T3 (pl) * 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
WO2014011732A1 (en) 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
AU2014318579A1 (en) * 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3149049B1 (en) 2014-05-27 2022-10-26 The University Of Queensland Il-22 for use in treating metabolic disorders
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
CN106146668A (zh) 2015-04-01 2016-11-23 中国人民解放军第二军医大学 长效白细胞介素22的制备方法及其用途
UA123772C2 (uk) * 2015-07-15 2021-06-02 Протагоніст Терепьютікс, Інк. Пептидний інгібітор рецептора інтерлейкіну-23 та спосіб лікування запального захворювання кишечнику (ibd)
KR20250145137A (ko) * 2017-08-03 2025-10-13 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
SG11202006259SA (en) 2018-01-26 2020-08-28 Genentech Inc Il-22 fc fusion proteins and methods of use
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
MX2022012822A (es) 2020-04-17 2023-01-04 Univ Leland Stanford Junior Polipeptidos modificados de interleucina-22 y usos de los mismos.
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2022238503A1 (en) 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089107A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
US20240108731A1 (en) 2024-04-04
PE20221279A1 (es) 2022-09-05
US20240252649A1 (en) 2024-08-01
JP7479539B2 (ja) 2024-05-08
IL292657A (en) 2022-07-01
CN118359699A (zh) 2024-07-19
JP2023083380A (ja) 2023-06-15
WO2021089875A1 (en) 2021-05-14
MX2022005547A (es) 2022-07-04
CN114761422B (zh) 2026-01-02
EP3819307A1 (en) 2021-05-12
US12226487B2 (en) 2025-02-18
US20220347304A1 (en) 2022-11-03
SA522432487B1 (ar) 2024-10-01
JP2023502005A (ja) 2023-01-20
US20260014257A1 (en) 2026-01-15
US20230381320A1 (en) 2023-11-30
KR20220097921A (ko) 2022-07-08
CA3160338A1 (en) 2021-05-14
US12447211B2 (en) 2025-10-21
PH12022551107A1 (en) 2023-11-20
CL2022001185A1 (es) 2023-02-03
AU2020378648A1 (en) 2022-06-23
US11806403B2 (en) 2023-11-07
BR112022008497A2 (pt) 2022-07-26
GEAP202415970A (en) 2024-12-25
EP4055035A1 (en) 2022-09-14
MY209488A (en) 2025-07-12
CO2022005889A2 (es) 2022-07-29
CR20220249A (es) 2022-08-19
CN114761422A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
GEAP202415970A (en) Therapeutic derivatives of interleukin-22
Baldo et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis.
JP5814177B2 (ja) 植物由来のエラスチン結合タンパク質リガンドおよびその使用方法
EP0486862A1 (en) Chimeric fibroblast growth factor
RU2014137321A (ru) ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
NZ603562A (en) Tear lipocalin muteins binding il-4 r alpha
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
PH12013502609A1 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
WO2023035632A1 (zh) 一种活性肽及其相关用途
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
MX2021004185A (es) Polipeptidos analogos de la amilina humana y sus metodos de uso.
MX9307983A (es) Derivados de aminoacidos de heterociclos como inhibidores de la proteina quinasa c.
KR102806029B1 (ko) 사이클릭 폴리펩타이드, 그것의 제조 방법 및 치료학적 용도
CN103834664B (zh) 重组表皮生长因子egf及其制备方法
US20150031611A1 (en) Highly Stabilized Epidermal Growth Factor Mutants
AR039629A1 (es) Antagonistas de proteinas mcp
CN104870470B (zh) 人松驰素类似物、其药物组合物及其在医药上的应用
JP5992529B2 (ja) ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
MX2023000945A (es) 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias.
MX2022013024A (es) Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos.
HRP20210441T1 (hr) Farmaceutski pripravak koji se sastoji od agonista receptora čimbenika rasta i proteina inhibitora adhezije za pretvaranje neoplastične stanice u neneoplastičnu stanicu i njegova upotreba
Song et al. High-efficiency production of bioactive recombinant human fibroblast growth factor 18 in Escherichia coli and its effects on hair follicle growth
WO2011157609A3 (en) Use of amino acid derivatives as agents for treating human perspiration, peptide derivatives, and compositions containing them